Study details
Enrolling now
Imaging SV2A in Mood Disorders
Yale University
NCT IDNCT02734602ClinicalTrials.gov data as of Apr 2026
Target enrollment
130
Study length
about 11 years
Ages
18–70
Locations
1 site in CT
What this study is about
Researchers are testing whether ketamine can reverse synaptic loss in the brain of people with depression or PTSD. The trial will involve imaging and PET scans to measure SV2A density, a protein related to synaptic function.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Ketamine
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)
Body systems
Psychiatry / Mental Health